Lupus & antiphospholipid syndrome
Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis
Authors' conclusion
We found lower risks of adverse CV and kidney outcomes and mortality with GLP-1RA use compared with DPP4i use among patients with lupus and T2D.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, US multicentre EHR database; secondary analysis in lupus nephritis (LN)LN: 267 and 324
- Participants
- 910 vs 1,004
- Exposure
- GLP-1RA vs DPP4i
- GLP-1RAn = 910
- DPP4in = 1,004reference
- Outcome
- Cardiovascular (CV) and kidney outcomes and mortality, GLP-1RA vs DPP4i
Methodological detailsretrospective cohort study, pragmatic target trial emulation, propensity score overlap weighting, US multicentre electronic health record database, Cox regression
- Retrospective cohort study
- Pragmatic target trial emulation
- Propensity score overlap weighting
- US multicentre electronic health record database
- Cox regression
Main finding
As reported in the abstract
GLP-1RA vs DPP4iHazard ratio (95% CI)
MACE
0.66(0.48–0.91)
VTE
0.49(0.24–0.97)
Kidney disease progression (eGFR decline ≥ 30% or new ESKD)
0.77(0.60–0.98)
All-cause mortality
0.26(0.10–0.68)
Observational data: associations, not effects.
Further findings
MACE and kidney disease progression in LN (secondary analysis)
- GLP-1RA use similarly associated with lower risks of MACE and kidney disease progression among patients with LN
Original publication
Glucagon‐Like Peptide‐1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis Rheumatol. Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →